Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ICON Public Limited Company (ICLR) stocks in Canada

Learn how to easily invest in ICON Public Limited Company stocks.

ICON Public Limited Company is a diagnostics & research business based in the US. ICON Public Limited Company stocks (ICLR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $214.46 – a decrease of 5.09% over the previous week. ICON Public Limited Company employs 37,960 staff and has a trailing 12-month revenue of around $4.4 billion.

How to buy shares in ICON Public Limited Company

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ICLR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy ICON Public Limited Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted ICON Public Limited Company's stock price?

Since the stock market crash in March caused by coronavirus, ICON Public Limited Company's stock price has had significant positive movement.

Its last market close was $266.39, which is 35.82% up on its pre-crash value of $170.98 and 155.47% up on the lowest point reached during the March crash when the stocks fell as low as $104.275.

If you had bought $1,000 worth of ICON Public Limited Company stocks at the start of February 2020, those stocks would have been worth $688.26 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,577.03.

ICON Public Limited Company stock price (NASDAQ:ICLR)

Use our graph to track the performance of ICLR stocks over time.

ICON Public Limited Company shares at a glance

Information last updated 2022-01-11.
Latest market close$266.39
52-week range$168.76 - $313.00
50-day moving average $283.47
200-day moving average $246.32
Wall St. target price$307.25
PE ratio 96.5941
Dividend yield N/A (0%)
Earnings per share (TTM) $2.94

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

ICON Public Limited Company price performance over time

Historical closes compared with the close of $266.39 from 2022-01-14

1 week (2022-01-07) -5.09%
1 month (2021-12-16) -6.32%
3 months (2021-10-15) -3.14%
6 months (2021-07-16) 22.60%
1 year (2021-01-15) 26.64%
2 years (2020-01-16) 52.12%
3 years (2019-01-16) 99.10%
5 years (2017-01-13) 224.51%

Is ICON Public Limited Company under- or over-valued?

Valuing ICON Public Limited Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ICON Public Limited Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

ICON Public Limited Company's P/E ratio

ICON Public Limited Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 97x. In other words, ICON Public Limited Company shares trade at around 97x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

ICON Public Limited Company's PEG ratio

ICON Public Limited Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9428. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ICON Public Limited Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

ICON Public Limited Company's EBITDA

ICON Public Limited Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $661.4 million.

The EBITDA is a measure of a ICON Public Limited Company's overall financial performance and is widely used to measure a its profitability.

ICON Public Limited Company financials

Revenue TTM $4.4 billion
Operating margin TTM 10.77%
Gross profit TTM $819.9 million
Return on assets TTM 2.83%
Return on equity TTM 3.68%
Profit margin 4.09%
Book value $97.90
Market capitalisation $22.6 billion

TTM: trailing 12 months

ICON Public Limited Company share dividends

We're not expecting ICON Public Limited Company to pay a dividend over the next 12 months.

Have ICON Public Limited Company's shares ever split?

ICON Public Limited Company's shares were split on a 2:1 basis on 12 August 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ICON Public Limited Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ICON Public Limited Company shares which in turn could have impacted ICON Public Limited Company's share price.

ICON Public Limited Company share price volatility

Over the last 12 months, ICON Public Limited Company's shares have ranged in value from as little as $168.76 up to $313. A popular way to gauge a stock's volatility is its "beta".

ICLR.US volatility(beta: 0.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ICON Public Limited Company's is 0.8875. This would suggest that ICON Public Limited Company's shares are less volatile than average (for this exchange).

ICON Public Limited Company overview

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site